Sort   by:  
 Page size 
ProteomicsRisk SNP rs11067228-mediated high-order chromatin interactions drive prostate cancer neuroendocrine differentiation through splicing factor SRRM4
Neuroendocrine prostate cancer is an aggressive disease characterized by early metastasis, drug resistance and poor prognosis. Genome-wide association studies (GWAS) previously identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer. SNP rs11067228 as a significant...
ORGANISM(S): Homo sapiens (Human) 
2026-02-09 | PXD055628 | Pride
Snp rs11067228  enhancer  long-range chromatin interaction  neuroendocrine differentiation  prostate cancer 
GenomicsThe risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (RNA-seq data set)
The risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (RNA-seq data set)
PRJNA1145310 | ENA
GenomicsThe risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (4C-seq data set)
The risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (4C-seq data set)
PRJNA1145309 | ENA
TranscriptomicsThe risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (RNA-seq data set)
Neuroendocrine prostate cancer is an aggressive disease characterized by early metastasis, drug resistance and poor prognosis. Genome-wide association studies (GWAS) previously identified the single nucleotide polymorphism (SNP) rs11067228 as a significant variant associated with castration-resistan...
ORGANISM(S): Homo sapiens 
2026-06-30 | GSE274155 | GEO
OtherThe risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (4C-seq data set)
Neuroendocrine prostate cancer is an aggressive disease characterized by early metastasis, drug resistance and poor prognosis. Genome-wide association studies (GWAS) previously identified the single nucleotide polymorphism (SNP) rs11067228 as a significant variant associated with castration-resistan...
ORGANISM(S): Homo sapiens 
2026-06-30 | GSE274153 | GEO
UnknownThe castration-resistant prostate cancer-associated SNP rs11067228 facilitates neuroendocrine differentiation through an enhancer-mediated chromatin interaction with SRRM4.
Not available
S-EPMC12837743 | biostudies-literature
GenomicsThe risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (ChIP-seq data set)
The risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (ChIP-seq data set)
PRJNA1145311 | ENA
GenomicsThe risk SNP rs11067228 promotes prostate cancer drug resistance and neuroendocrine differentiation through 3D chromatin interactions (ChIP-seq data set)
We performed ChIP-seq in 22Rv1, C4-2B, LNCaP and RWPE1 cells to determine the binding of H3K27ac.
ORGANISM(S): Homo sapiens 
2026-06-30 | GSE274154 | GEO
UnknownValidation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.
Not available
S-EPMC3830710 | biostudies-literature
Sort   by:  
 Page size